{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:25:01Z","timestamp":1740176701650,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tumorigenesis in NAFLD\/NASH-induced HCC is unique and may affect the effectiveness of trans-arterial radioembolization in this population. The purpose of this study was to retrospectively compare the effectiveness of trans-arterial radioembolization for the treatment of hepatocellular carcinoma (HCC) between patients with non-alcoholic steatohepatitis (NASH)\/non-alcoholic fatty liver disease (NAFLD) and non-NASH\/NAFLD liver disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Consecutive patients with HCC who underwent TARE at a single academic institution were retrospectively reviewed. Outcome measures including overall survival (OS), local progression-free survival (PFS), and hepatic PFS as assessed by modified response evaluation criteria in solid tumors (mRECIST) were recorded. Kaplan\u2013Meier and Cox proportional hazard models were utilized to compare progression-free survival and overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>138 separate HCCs in patients treated with TARE between July 2013 and July 2022 were retrospectively identified. Etiologies of HCC included NASH\/NAFLD (30\/122, 22%), HCV (52\/122, 43%), alcoholic liver disease (25\/122, 21%), and combined ALD\/HCV (14\/122, 11%). NASH\/NAFLD patients demonstrated a significantly higher incidence of type 2 diabetes mellitus (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). There was no significant difference in overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.928), local progression-free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.339), or hepatic progression-free survival between the cohorts (<jats:italic>p<\/jats:italic>\u2009=\u20090.946) by log-rank analysis. When NASH\/NAFLD patients were compared to all combined non-NASH\/NAFLD patients, there was no significant difference in OS (HR 1.1, 95% C.I. 0.32\u20133.79, <jats:italic>p<\/jats:italic>\u2009=\u20090.886), local PFS (HR 1.2, 95% C.I. 0.58\u20132.44, <jats:italic>p<\/jats:italic>\u2009=\u20090.639), or hepatic PFS (HR 1.3, 95% C.I. 0.52\u20133.16, <jats:italic>p<\/jats:italic>\u2009=\u20090.595) by log-rank analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TARE appears to be an equally effective treatment for NASH\/NAFLD-induced HCC when compared to other causes of HCC. Further studies in a larger cohort with additional subgroup analyses are warranted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00261-024-04295-8","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T05:01:27Z","timestamp":1714971687000},"page":"2714-2725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis\/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-4901","authenticated-orcid":false,"given":"Christopher","family":"Brunson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Struycken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Ref","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Hannallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Woodhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamar","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"5","key":"4295_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","volume":"10","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao M, Arai Y, et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg Nutr. 2021;10(5):661-671. doi:https:\/\/doi.org\/10.21037\/hbsn-21-260","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"4295_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diii.2022.01.006","volume":"103","author":"S Young","year":"2022","unstructured":"Young S, Sanghvi T, Sharma S, et al. Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma. Diagn Interv Imaging. 2022;103(3):143-149. doi:https:\/\/doi.org\/10.1016\/j.diii.2022.01.006","journal-title":"Diagn Interv Imaging"},{"key":"4295_CR3","doi-asserted-by":"publisher","unstructured":"Lam M, Garin E, Maccauro M, et al. 2022 A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. (0123456789). https:\/\/doi.org\/10.1007\/s00259-022-05774-0","DOI":"10.1007\/s00259-022-05774-0"},{"issue":"3","key":"4295_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693. doi:https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"issue":"4","key":"4295_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jhep.2022.03.037","volume":"77","author":"R Salem","year":"2022","unstructured":"Salem R, Tselikas L, De Baere T. Interventional treatment of hepatocellular carcinoma. J Hepatol. 2022;77(4):1205-1206. doi:https:\/\/doi.org\/10.1016\/j.jhep.2022.03.037","journal-title":"J Hepatol"},{"issue":"9","key":"4295_CR6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","volume":"26","author":"A Sanyal","year":"2010","unstructured":"Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26(9):2183-2191. doi:https:\/\/doi.org\/10.1185\/03007995.2010.506375","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"4295_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100192","volume":"2","author":"P Burra","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Reports. 2020;2(6):100192. doi:https:\/\/doi.org\/10.1016\/j.jhepr.2020.100192","journal-title":"JHEP Reports"},{"issue":"24","key":"4295_CR8","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1002\/cncr.24687","volume":"115","author":"AB Siegel","year":"2009","unstructured":"Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma. Cancer. 2009;115(24):5651-5661. doi:https:\/\/doi.org\/10.1002\/cncr.24687","journal-title":"Cancer"},{"issue":"11","key":"4295_CR9","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, Vipani A, Bresee C, et al. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. American Journal of Gastroenterology. 2018;113(11):1649-1659. doi:https:\/\/doi.org\/10.1038\/s41395-018-0088-6","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"4295_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","volume":"16","author":"NE Rich","year":"2018","unstructured":"Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198-210.e2. doi:https:\/\/doi.org\/10.1016\/j.cgh.2017.09.041","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4295_CR11","doi-asserted-by":"publisher","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. 2018 Mechanisms of NAFLD Development and Therapeutic Strategies. 24. https:\/\/doi.org\/10.1038\/s41591-018-0104-9","DOI":"10.1038\/s41591-018-0104-9"},{"issue":"6","key":"4295_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5306\/wjco.v8.i6.429","volume":"8","author":"A Said","year":"2017","unstructured":"Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol. 2017;8(6):429-436. doi:https:\/\/doi.org\/10.5306\/wjco.v8.i6.429","journal-title":"World J Clin Oncol."},{"key":"4295_CR13","doi-asserted-by":"publisher","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. https:\/\/doi.org\/10.1038\/s41575-019-0145-7","DOI":"10.1038\/s41575-019-0145-7"},{"issue":"6","key":"4295_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5306\/wjco.v8.i6.429","volume":"8","author":"A Said","year":"2017","unstructured":"Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma World Journal of Clinical Oncology. World J Clin Oncol. 2017;8(6):429-436. doi:https:\/\/doi.org\/10.5306\/wjco.v8.i6.429","journal-title":"World J Clin Oncol"},{"issue":"7854","key":"4295_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450-456. doi:https:\/\/doi.org\/10.1038\/s41586-021-03362-0","journal-title":"Nature"},{"key":"4295_CR16","doi-asserted-by":"publisher","unstructured":"Benhammou J, Aby elizabeth S, Shirvanian G, et al. improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. https:\/\/doi.org\/10.1038\/s41598-020-66507-7","DOI":"10.1038\/s41598-020-66507-7"},{"issue":"4","key":"4295_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.6004\/jnccn.2018.7105","volume":"17","author":"CA Hester","year":"2019","unstructured":"Hester CA, Rich NE, Singal AG, Yopp AC. Comparative analysis of nonalcoholic steatohepatitis - Versus viral hepatitis- and alcohol-related liver disease-related hepatocellular carcinoma. JNCCN Journal of the National Comprehensive Cancer Network. 2019;17(4):322-329. doi:https:\/\/doi.org\/10.6004\/jnccn.2018.7105","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"4295_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","volume":"5","author":"JK Dyson","year":"2014","unstructured":"Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-218. doi:https:\/\/doi.org\/10.1136\/flgastro-2013-100403","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"4295_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1055\/s-0035-1564708","volume":"32","author":"RC Gaba","year":"2015","unstructured":"Gaba RC. Planning Arteriography for Yttrium-90 Microsphere Radioembolization. Semin Intervent Radiol. 2015;32(4):428-438. doi:https:\/\/doi.org\/10.1055\/s-0035-1564708","journal-title":"Semin Intervent Radiol."},{"issue":"5","key":"4295_CR20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021;74(5):2342-2352. doi:https:\/\/doi.org\/10.1002\/hep.31819","journal-title":"Unresectable HCC: The LEGACY Study. Hepatology"},{"issue":"3","key":"4295_CR21","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00330-020-07231-8","volume":"31","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Kudla A, Weinstein JL, et al. Yttrium-90 radioembolization using MIRD dosimetry with resin microspheres. Eur Radiol. 2021;31(3):1316-1324. doi:https:\/\/doi.org\/10.1007\/s00330-020-07231-8","journal-title":"Eur Radiol"},{"issue":"6","key":"4295_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clinical Cancer Research. 2013;19(6):1312-1314. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3796","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"4295_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000501484","volume":"8","author":"C Schotten","year":"2019","unstructured":"Schotten C, Bechmann LP, Manka P, et al. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer. 2019;8(6):491-504. doi:https:\/\/doi.org\/10.1159\/000501484","journal-title":"Liver Cancer"},{"issue":"1","key":"4295_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1197-x","volume":"15","author":"A Weinmann","year":"2015","unstructured":"Weinmann A, Alt Y, Koch S, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;15(1):1-9. doi:https:\/\/doi.org\/10.1186\/s12885-015-1197-x","journal-title":"BMC Cancer"},{"issue":"6","key":"4295_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.25536","volume":"55","author":"SK Reddy","year":"2012","unstructured":"Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55(6):1809-1819. doi:https:\/\/doi.org\/10.1002\/hep.25536","journal-title":"Hepatology"},{"issue":"1","key":"4295_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-66507-7","volume":"10","author":"JN Benhammou","year":"2020","unstructured":"Benhammou JN, Aby ES, Shirvanian G, Manansala K, Hussain SK, Tong MJ. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma. Sci Rep. 2020;10(1):1-9. doi:https:\/\/doi.org\/10.1038\/s41598-020-66507-7","journal-title":"Sci Rep"},{"issue":"1","key":"4295_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00270-019-02363-x","volume":"43","author":"S Young","year":"2020","unstructured":"Young S, Sanghvi T, Rubin N, et al. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis. Cardiovasc Intervent Radiol. 2020;43(1):65-75. doi:https:\/\/doi.org\/10.1007\/s00270-019-02363-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4295_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1). doi:https:\/\/doi.org\/10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"4295_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","volume":"7","author":"C Mosconi","year":"2015","unstructured":"Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7(5):738-752. doi:https:\/\/doi.org\/10.4254\/wjh.v7.i5.738","journal-title":"World J Hepatol"},{"issue":"25","key":"4295_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101084","volume":"2019","author":"US Srinivas","year":"2018","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25(October 2018):101084. doi:https:\/\/doi.org\/10.1016\/j.redox.2018.101084","journal-title":"Redox Biol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04295-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:05:07Z","timestamp":1722837907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["4295"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04295-8","relation":{},"ISSN":["2366-0058"],"issn-type":[{"type":"electronic","value":"2366-0058"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shamar Young has received research grants from Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study has obtained IRB approval from the University of Arizona IRB and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}